BioSpace News Archive

Alligator Bioscience announced interim safety data from its ongoing clinical Phase I study of the drug candidate ATOR-1017, its wholly owned 4-1BB antibody in development for the treatment of metastasized cancer.

So-Young International Inc., the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, announced its unaudited financial results for the three months ended June 30, 2020.

Sarah Cannon, the Cancer Institute of HCA Healthcare, and Lyell Immunopharma announced a strategic collaboration for the advancement of oncology-focused immune-effector, or T-Cell, therapies.

A Silicon Valley Bank credit facility and additional financing from other lenders increase operational flexibility and support the company’s long-term strategy

Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,751,413 providing product protection for SRK-015, including composition of matter and methods of use, with an expiry of January 2037. “We are at the forefro

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts1,” by Wittbrodt, Bremner et. al. in the journal Brain Stimulation.

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that management will present at the LD 500 Virtual Conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020.

AMT-101 is the only oral gastrointestinal-targeted IL-10 biologic designed to be actively transported through the intestinal epithelium barrier into the GI tissue, the primary site of inflammation in UC

Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis B virus (HBV) core inhibitor candidate ABI-H0731 in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, today announced that an e-poster presentation has been accepted at the International Association for the Study of Lung Cancer’s